Articles related to LYMPHOMA

Adults with confirmed R/R aNHL within 12 months after first-line (1L) chemo-immunotherapy were eligible for the randomized Phase III study, which demonstrated that tisagenlecleucel (tisa-cel) as second-line (2L) treatment in R/R aNHL patients did not have a higher event-free survival (EFS) vs. the standard-of-care (SOC). Read this late-breaking abstract from the ASH Annual Meeting & Exhibition to discover the contributing factors leading to the results, as well as how insights from this study will inform use of cellular treatment in the 2L R/R aNHL setting and the design of future CAR-T trials.

A late-breaking abstract from the ASH Annual Meeting & Exhibition. In this double-blind, placebo-controlled, international study of 879 patients (median age: 65 (range 19–80) years; IPI 3–5 (62%)), the pola-R-CHP combination demonstrated a 27% reduction in the relative risk of disease progression, relapse, or death compared with R-CHOP, with a similar safety profile in the first-line treatment of patients with DLBCL.

DLBCL is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. This has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment paradigm in recent years, as several DLBCL subtypes have inferior survival after standard R-CHOP therapy. So how do you choose? In this review the authors conclude with proposed clinical management scenarios in which DA-R-EPOCH may be preferred, including some for patient populations in which the use of R-CHOP vs. DA-R-EPOCH is controversial.

Clinical Advances in Hematology & Oncology talks with Sonali M. Smith, MD, an Elwood V. Jensen Professor in Medicine and Chief, Section of Hematology/Oncology at the University of Chicago, about all things transformed lymphoma, including risk factors, distinguishing characteristics, pathogenesis, traditional treatment approaches, treatment goals, new treatment strategies, and other promising areas of research.

Publication: ASH Clinical NewsOriginal Source: Journal of the National Care InstituteDesign: Assessment of longitudinal changes in memory, attention, and executive function in men and women with lymphoma (n=248; 62.5% male) prior to and six months after initiation of chemotherapy. A group of age- and sex-matched people without cancer was used as a control arm (n=212; 59% male).Results: At baseline, patients with lymphoma self-reported significantly more issues on the FACT-Cog scale (perceived cognitive impairment [PCI] and total scores) compared with sex-matched controls (p<0.05). In addition, patients with lymphoma reported significantly more attentional difficulty (p=0.01) and significantly greater PCI (p<0.03).

Publication: Blood AdvancesStudy Design: Prospective study with unmatched health care workforce control group, receiving either Moderna or Pfizer COVID vaccination.Study Population: 23 patients with CLL (61%), lymphoma (39%) (including DLBCL), MCL (13%) and 4% with less common lymphomas.Outcome: Lymphoma patients had significantly lower anti-S IgG titers 28 days post-vaccination compared with controls. Related Article: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with B-Cell Non-Hodgkin Lymphoma